Syndesi Therapeutics

Technology
Biotechnology
Health Care
Medical
Therapeutics

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain).

Suggest edits

Type

B2c

Founded

2018

Raised

$21M

Follow us

Also headquartered in Louvain-La-Neuve

Qualifio
Keemotion
Vives Fund
InternetVista
GetSmily
Elimity
Vives Louvain Technology Fund
Lean FUND
Tessares
WinBooks

Companies in the same industry

Gadeta
Click Therapeutics
Annexon Biosciences
Theranica
Hookipa Pharma
DMD Therapeutics
Engage Therapeutics
NorthSea Therapeutics
Crescendo Biologics
Innovative Cellular Therapeutics

Alexa global traffic share

Built with ❤︎ by Datalicious ©2022
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 1

Add info

Latest funding

€17,000,000

Venture capital (Series A) - 2018

Johnson & Johnson Innovation Fountain Healthcare Partners Johnson & Johnson +3

Team Size

Employees

I work here

Location

Louvain-La-Neuve , Belgium

Headquarters

Explore Louvain-La-Neuve

AbbVie buys Syndesi Therapeutics for up to $1bn

€17,000,000 Venture capital (Series A)

Index

By TNW